

Erratum

Therapeutic potential of EGFR/mTOR/Nf-kb targeting small molecule for the treatment of non-small cell lung cancer: Am J Cancer Res. 2023; 13(6): 2598-2616

Bashir Lawal^{1,2*}, Yu-Cheng Kuo^{3,4*}, Alexander TH Wu^{5,6,7,8}, Hsu-Shan Huang^{8,9,10,11,12}

¹UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15260, USA; ²Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15260, USA; ³Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan; ⁴School of Post-baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan; ⁵The PhD Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; ⁶Clinical Research Center, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan; ⁷TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 11031, Taiwan; ⁸Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan; ⁹PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 11031, Taiwan; ¹⁰Graduate Institute for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan; ¹¹School of Pharmacy, National Defense Medical Center, Taipei 11490, Taiwan; ¹²PhD Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei 11031, Taiwan. *Equal contributors.

Received May 26, 2024; Accepted May 31, 2024; Epub June 25, 2024; Published June 30, 2024

In **Figure 5B**, we regretfully identified an error: the NF- κ B Western blot from Figure 4D was mistakenly used to represent SOX2 in the right panel (H1975 spheroid) of **Figure 5B**. We have corrected this mistake in the revised figure. This correction does not alter any interpretations or conclusions of the study. We sincerely apologize for this oversight and any confusion it may have caused.

The corrected **Figure 5** is as follows.

Address correspondence to: Alexander TH Wu, The PhD Program of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan. E-mail: chaw1211@tmu.edu.tw; Hsu-Shan Huang, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan. E-mail: huanghs99@tmu.edu.tw




Figure 5. Effects of NLOC-O15A treatment on the spheroid-forming abilities of H1299 and H1975 cells. Graphical representation of the inhibitory effects of NLOC-O15A on the (A) spheroid-forming abilities of H1299 and H1975 cells. Scale bar 50 μ m. (B) Western blot analysis showing that NLOC-O15A suppressed expression levels of ALDH, c-Myc, and SOX2 in both H1299 and H1975 spheroid. * $P < 0.05$, ** $P < 0.01$.